Fibrosis News and Research

RSS

Fibrosis is the growth of fibrous tissue.

Immune cells prevent the lungs' protective barrier from healing after viral infections

Investigators involved in a multicenter study co-led by Cedars-Sinai discovered a pathway by which immune cells prevent the lungs' protective barrier from healing after viral infections like COVID-19.

4 Sep 2024

Autophagy in HPCs modulates exosomal miRNAs to inhibit liver fibrosis

The study investigates the role of autophagy in hepatic progenitor cells (HPCs) and its potential to modulate exosomal microRNAs (miRNAs) to inhibit liver fibrosis in the context of schistosomiasis, a disease caused by parasitic flatworms that can lead to severe organ damage, particularly to the liver.

2 Sep 2024

Study reveals key role of A20 protein in controlling inflammation in liver disease

Many individuals worldwide suffer from chronic liver disease (CLD), which poses significant concerns for its tendency to lead to hepatocellular carcinoma or liver failure. CLD is characterized by inflammation and fibrosis.

29 Aug 2024

Understanding the mechanisms of cardiac fibrosis

The article explores the role of the m6A reader YTHDF1 in cardiac fibrosis, a condition characterized by the excessive accumulation of extracellular matrix proteins, leading to the stiffening of the heart and impaired function. Cardiac fibrosis is a common pathological process in various cardiovascular diseases, including hypertension, myocardial infarction, and heart failure.

29 Aug 2024

Study reveals the role of blood clotting in COVID-19

In a study that reshapes what we know about COVID-19 and its most perplexing symptoms, scientists have discovered that the blood coagulation protein fibrin causes the unusual clotting and inflammation that have become hallmarks of the disease, while also suppressing the body's ability to clear the virus.

29 Aug 2024

TCT 2024 to feature latest advances in interventional cardiovascular medicine

The Cardiovascular Research Foundation is pleased to announce the late-breaking clinical trials and science to be featured at TCT 2024.

28 Aug 2024

Protein from gut worms accelerates skin regeneration and reduces scarring

Researchers at Rutgers University in New Jersey have discovered that a protein produced by parasitic worms in the gut enhances wound healing in mice.

23 Aug 2024

Advances in endoscopic treatment for inflammatory bowel disease complications

Inflammatory bowel diseases (IBD), comprising Crohn's disease (CD) and ulcerative colitis (UC), are chronic inflammatory conditions affecting the gastrointestinal tract.

23 Aug 2024

New insights into macrophages' role in MASH and liver fibrosis

Formerly known as nonalcoholic steatohepatitis, metabolic dysfunction-associated steatohepatitis (MASH) is an inflammatory disease characterized by liver scarring or fibrosis that progressively impairs liver function.

22 Aug 2024

Novel drug-carrying molecule slips past the lung's natural defenses to cure disease

A drug-carrying molecule designed to cure disease by slipping past the lung's natural defenses offers new hope for people with chronic or deadly respiratory diseases, say its creators, researchers in assistant professor Liheng Cai's Soft Biomatter Lab at the University of Virginia School of Engineering and Applied Science.

22 Aug 2024

Python's remarkable physiology could lead to new medical breakthroughs

Researchers fed pythons who had fasted for 28 days a meal of 25% of their body weight and compared them to snakes who had not been fed.

22 Aug 2024

Breakthrough treatment reduces liver fibrosis in Hepatitis C patients

HCV infection is the underlying cause for chronic Hepatitis C (CHC), liver cirrhosis, and liver cancer or hepatocellular carcinoma (HCC). In 2019, over 2,90,000 people died of HCV-related diseases. Recent medical advancement made a new breakthrough treatment available for patients with hepatitis C. DAAs that block replication of HCV has dramatically transformed the treatment approach with around 90% effective anti-viral response rates. However, it is unclear whether DAAs impact the severity of disease burden caused by liver fibrosis.

21 Aug 2024

Study reveals new insights into urea cycle's role in fatty liver disease

An Indiana University School of Medicine physician scientist is making strides in understanding the molecular origins of fatty liver disease, a leading cause of liver failure in the United States.

16 Aug 2024

IU research sheds light on urea cycle defects and fatty liver disease

An Indiana University School of Medicine physician scientist is making strides in understanding the molecular origins of fatty liver disease, a leading cause of liver failure in the United States.

13 Aug 2024

New ultrasound-based tool offers precise measurement of lung diseases

Researchers have established a suite of parameters that can be determined using ultrasound to quantitatively measure different physical characteristics of the lung.

13 Aug 2024

New research identifies key protein complex in cellular quality control

Anyone who's tried to neatly gather a fitted sheet can tell you: folding is hard. Get it wrong with your laundry and the result can be a crumpled, wrinkled mess of fabric, but when folding fails among the approximately 7,000 proteins with an origami-like complexity that regulate essential cellular functions, the result can lead to one of a multitude of serious diseases ranging from emphysema and cystic fibrosis to Alzheimer's disease.

12 Aug 2024

Insilico Medicine's pan-TEAD inhibitor ISM6331 receives FDA IND clearance for mesothelioma treatment

Insilico Medicine ("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced ISM6331, potential best-in-class pan-TEAD inhibitor, has received the U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) clearance for the treatment of mesothelioma, following the grant of Orphan Drug Designation (ODD) in June 2024. It brings the total number of IND-approved molecules of Insilico to nine.

8 Aug 2024